KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 23, 2017, Pages E4676-E4685

  Quinti, Luisa ^a   Naidu, Sharadha Dayalan ^b   Träger, Ulrike ^c   Chen, Xiqun ^a   Kegel Gleason, Kimberly ^a   Llères, David ^d   Connolly, Colúm ^e   Chopra, Vanita ^a   Low, Cho ^f   Moniot, Sébastien ^g   Sapp, Ellen ^a   Tousley, Adelaide R ^a   Vodicka, Petr ^a   Van Kanegan, Michael J ^d,h   Kaltenbach, Linda S ^h   Crawford, Lisa A ⁱ   Fuszard, Matthew ^g   Higgins, Maureen ^b   Miller, James R C ^c   Farmer, Ruth E ^j   Potluri, Vijay ^k   Samajdar, Susanta ^k   Meisel, Lisa ^g   Zhang, Ningzhe ^l   Snyder, Andrew ^m   Stein, Ross ^m   Hersch, Steven M ^a   Ellerby, Lisa M ^l   Weerapana, Eranthie ⁱ   Schwarzschild, Michael A ^a   Steegborn, Clemens ^g   Leavitt, Blair R ^e   Degterev, Alexei ^f   Tabrizi, Sarah J ^c   Lo, Donald C ^h   DiFiglia, Marian ^a   Thompson, Leslie M ⁿ   Dinkova Kostova, Albena T ^b,o   Kazantsev, Aleksey G ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF BAYREUTH   (Germany)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ BOSTON COLLEGE   (United States)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k Aurigene Discovery Technologies Limited   (India)

^l BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^m Targanox   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Antiinflammatory responses; Human neural stem cells; Huntington's disease; KEAP1 NRF2 ARE signaling; NRF2 inducer

Indexed keywords

CYSTEINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; TRIAZOLE; TUMOR NECROSIS FACTOR; CYTOKINE; KEAP1 PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, HUMAN; NFE2L2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MICROGLIA; MONOCYTE; MOUSE; MUTATION; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; ADULT; AGED; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; HEK293 CELL LINE; INTOXICATION; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; PROTEIN CONFORMATION; RAT; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; BRAIN; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MIDDLE AGED; MPTP POISONING; NEURAL STEM CELLS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PROTEIN CONFORMATION; RATS; SIGNAL TRANSDUCTION;

EID: 85020286880     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614943114     Document Type: Article

References (99)

1. Itoh K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86.
2. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116.
3. Baird L, Dinkova-Kostova AT (2011) The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85:241-272.
4. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004) The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: Oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24:8477-8486.
5. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism. Biol Chem 387: 1311-1320.
6. Tong KI, et al. (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27:7511-7521.
7. Zhang DD, Hannink M (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemo-preventive agents and oxidative stress. Mol Cell Biol 23:8137-8151.
8. McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278:21592-21600.
9. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24:10941-10953.
10. Kobayashi A, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139.
11. Dinkova-Kostova AT, et al. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99:11908-11913.
12. McMahon M, Lamont DJ, Beattie KA, Hayes JD (2010) Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci USA 107:18838-18843.
13. Baird L, Llères D, Swift S, Dinkova-Kostova AT (2013) Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci USA 110:15259-15264.
14. Baird L, Dinkova-Kostova AT (2013) Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells. Biochem Biophys Res Commun 433:58-65.
15. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA (2003) Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278: 12029-12038.
16. Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199-218.
17. Kobayashi EH, et al. (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7:11624.
18. Liu H, Dinkova-Kostova AT, Talalay P (2008) Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA 105:15926-15931.
19. Lee DH, Gold R, Linker RA (2012) Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci 13:11783-11803.
20. Knatko EV, et al. (2015) Nrf2 activation protects against solar-simulated ultraviolet radiation in mice and humans. Cancer Prev Res 8:475-486.
21. Browne SE, Beal MF (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8:2061-2073.
22. Möller T (2010) Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) 117:1001-1008.
23. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
24. Sorolla MA, et al. (2012) Protein oxidation in Huntington disease. Biofactors 38: 173-185.
25. Stack EC, Matson WR, Ferrante RJ (2008) Evidence of oxidant damage in Huntington's disease: Translational strategies using antioxidants. Ann N Y Acad Sci 1147:79-92.
26. Li X, et al. (2010) Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci 30:4552-4561.
27. Johri A, Beal MF (2012) Antioxidants in Huntington's disease. Biochim Biophys Acta 1822:664-674.
28. Tsunemi T, et al. (2012) PGC-1a rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 4:142ra197.
29. Sorolla MA, et al. (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667-678.
30. Ellrichmann G, et al. (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 6:e16172.
31. Stack C, et al. (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49:147-158.
32. Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neu-roinflammation. Mol Immunol 44:999-1010.
33. Pizza V, Agresta A, D'Acunto CW, Festa M, Capasso A (2011) Neuroinflamm-aging and neurodegenerative diseases: An overview. CNS Neurol Disord Drug Targets 10:621-634.
34. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: Role for cytokines. Curr Pharm Des 11:999-1016.
35. Phani S, Loike JD, Przedborski S (2012) Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 18:S207-S209.
36. Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87:10-20.
37. Dalrymple A, et al. (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6: 2833-2840.
38. Silvestroni A, Faull RL, Strand AD, Möller T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 20:1098-1103.
39. Sapp E, et al. (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161-172.
40. Björkqvist M, et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205:1869-1877.
41. Wild E, et al. (2011) Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr 3:RRN1231.
42. Pavese N, et al. (2006) Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 66:1638-1643.
43. Tai YF, et al. (2007) Imaging microglial activation in Huntington's disease. Brain Res Bull 72:148-151.
44. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47.
45. Politis M, et al. (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Hum Brain Mapp 32:258-270.
46. Quinti L, et al. (2016) SIRT2-and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington's disease models. Cell Chem Biol 23:849-861.
47. Williamson TP, Johnson DA, Johnson JA (2012) Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology 33:272-279.
48. Kaidery NA, et al. (2013) Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 18:139-157.
49. Bezard E, Przedborski S (2011) A tale on animal models of Parkinson's disease. Mov Disord 26:993-1002.
50. Prochaska HJ, Santamaria AB (1988) Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme inducers. Anal Biochem 169:328-336.
51. Fahey JW, Dinkova-Kostova AT, Stephenson KK, Talalay P (2004) The "Prochaska" microtiter plate bioassay for inducers of NQO1. Methods Enzymol 382:243-258.
52. Zhang Y, Talalay P, Cho CG, Posner GH (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399-2403.
53. Takaya K, et al. (2012) Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53:817-827.
54. Fox RJ, et al. (2014) BG-12 (dimethyl fumarate): A review of mechanism of action, efficacy, and safety. Curr Med Res Opin 30:251-262.
55. Outeiro TF, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317:516-519.
56. Wakabayashi N, et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35:238-245.
57. Wakabayashi N, et al. (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040-2045.
58. Benedict AL, Knatko EV, Dinkova-Kostova AT (2012) The indirect antioxidant sulfor-aphane protects against thiopurine-mediated photooxidative stress. Carcinogenesis 33:2457-2466.
59. Ludtmann MH, Angelova PR, Zhang Y, Abramov AY, Dinkova-Kostova AT (2014) Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem J 457:415-424.
60. Ujjainwalla F, Walsh TF (2001) Total syntheses of 6-and 7-azaindole derived GnRH antagonists. Tetrahedron Lett 42:6441-6445.
61. Polucci P, et al. (2013) Alkylsulfanyl-1, 2, 4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J Med Chem 56:437-450.
62. Hur W, et al. (2010) A small-molecule inducer of the antioxidant response element. Chem Biol 17:537-547.
63. Eggler AL, Luo Y, van Breemen RB, Mesecar AD (2007) Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem Res Toxicol 20:1878-1884.
64. Fourquet S, Guerois R, Biard D, Toledano MB (2010) Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem 285:8463-8471.
65. Linker RA, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678-692.
66. Cleasby A, et al. (2014) Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One 9:e98896.
67. Weerapana E, et al. (2010) Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468:790-795.
68. Qian Y, et al. (2013) An isotopically tagged azobenzene-based cleavable linker for quantitative proteomics. Chem Bio Chem 14:1410-1414.
69. Eng JK, McCormack AL, Yates JR (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5:976-989.
70. Tabb DL, McDonald WH, Yates JR, 3rd (2002) DTASelect and Contrast: Tools for assembling and comparing protein identifications from shotgun proteomics. J Proteome Res 1:21-26.
71. Weerapana E, Speers AE, Cravatt BF (2007) Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)-a general method for mapping sites of probe modification in proteomes. Nat Protoc 2:1414-1425.
72. Baird L, Swift S, Llères D, Dinkova-Kostova AT (2014) Monitoring Keap1-Nrf2 interactions in single live cells. Biotechnol Adv 32:1133-1144.
73. Bertrand HC, et al. (2015) Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1-Nrf2 protein-protein interaction. J Med Chem 58:7186-7194.
74. Jung KA, Kwak MK (2010) The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 15:7266-7291.
75. Innamorato NG, et al. (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181:680-689.
76. Koh K, et al. (2011) Transcription factor Nrf2 suppresses LPS-induced hyperactivation of BV-2 microglial cells. J Neuroimmunol 233:160-167.
77. Hornung V, et al. (2008) Silica crystals and aluminum salts activate the NALP3 in-flammasome through phagosomal destabilization. Nat Immunol 9:847-856.
78. Träger U, et al. (2013) JAK/STAT signalling in Huntington's disease immune cells. PloS Curr, 10.1371/currents.hd.5791c897b5c3bebeed93b1d1da0c0648.
79. Slow EJ, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567.
80. Kwan W, et al. (2012) Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 32:133-142.
81. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
82. Ritch JJ, et al. (2012) Multiple phenotypes in Huntington disease mouse neural stem cells. Mol Cell Neurosci 50:70-81.
83. An MC, et al. (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11:253-263.
84. Lee OH, Jain AK, Papusha V, Jaiswal AK (2007) An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem 282:36412-36420.
85. Crotti A, et al. (2014) Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 17:513-521.
86. Lastres-Becker I, et al. (2014) Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain 137:78-91.
87. HD iPSC Consortium (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264-278.
88. Ernst A, et al. (2014) Neurogenesis in the striatum of the adult human brain. Cell 156: 1072-1083.
89. Jin YN, et al. (2013) Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One 8:e57932.
90. Xu K, et al. (2006) Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J Neurosci 26:535-541.
91. Chen X, et al. (2013) Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci USA 110:300-305.
92. Ehrlich ME, et al. (2001) ST14A cells have properties of a medium-size spiny neuron. Exp Neurol 167:215-226.
93. Quinti L, et al. (2010) Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PloS Curr, 10.1371/currents.RRN1172.
94. Llères D, James J, Swift S, Norman DG, Lamond AI (2009) Quantitative analysis of chromatin compaction in living cells using FLIM-FRET. J Cell Biol 187:481-496.
95. Marder K, et al.; Huntington Study Group (2000) Rate of functional decline in Huntington's disease. Neurology 54:452-458.
96. Chopra V, et al. (2012) The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep 2:1492-1497.
97. Chen X, et al. (2015)Thesirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One 10:e0116919.
98. National Research Council (2011) Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, DC), 8th Ed.
99. Zhang BR, et al. (2012) CCG polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with Huntington's disease in mainland Chinese families. J Neurol Sci 312:92-96.